Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria

Overview

Journal touchREV Endocrinol

Specialty Endocrinology

Date 2023 Jan 25

PMID 36694889

Authors

Luis DMarco

Xavier Guerra-Torres

Iris Viejo

Luis Lopez-Romero

Alejandra Yugueros

Valmore Bermidez

Affiliations

Soon will be listed here.

Abstract

Diabetic kidney disease (DKD) is the leading cause of chronic and end-stage kidney disease worldwide. Its pathogenic mechanism is complex, and it can affect the entire structures of the kidneys such as the glomerulus, tubules and interstitium. Currently, the urinary albumin excretion rate and the estimated glomerular filtration rate are widely accepted as diagnostic criteria. However, some studies have reported a different or non-classical clinical course of DKD, with some patients showing declined kidney function with normal levels of albuminuria, known as the 'non-albuminuric DKD' phenotype. The pathogenesis of this phenotype remains unclear, but some clinical and pathological features have been postulated. This review explores the evidence regarding this topic.

Citing Articles

Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor α) in Diabetic Kidney Disease (DKD).

Jonny , Sitepu E, Hernowo B, Chiuman L, Lister I, Putranto T Curr Issues Mol Biol. 2024; 46(12):13662-13674.

PMID: 39727944 PMC: 11727525. DOI: 10.3390/cimb46120816.

The Potential of Anti-Inflammatory DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus.

Jonny J, Sitepu E, Lister I, Chiuman L, Putranto T Vaccines (Basel). 2024; 12(9).

PMID: 39340004 PMC: 11435532. DOI: 10.3390/vaccines12090972.

Role of Urinary Matrix Metalloproteinase-7 (MMP-7) as an Early Marker of Renal Dysfunction in Diabetic Individuals: A Cross-Sectional Study.

Sarangi R, Sahu D, Rout N, Padarabinda Tripathy K, Patra S, Bahinipati J Cureus. 2024; 16(8):e66392.

PMID: 39246865 PMC: 11379343. DOI: 10.7759/cureus.66392.

Identification of a New RNA and Protein Integrated Biomarker Panel Associated with Kidney Function Impairment in DKD: Translational Implications.

Scamporrino A, Di Mauro S, Filippello A, Di Marco G, Di Pino A, Scicali R Int J Mol Sci. 2023; 24(11).

PMID: 37298364 PMC: 10253864. DOI: 10.3390/ijms24119412.

References

Pichaiwong W, Homsuwan W, Leelahavanichkul A . The prevalence of normoalbuminuria and renal impairment in type 2 diabetes mellitus . Clin Nephrol. 2019; 92(2):73-80. DOI: 10.5414/CN109606. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Warren B, Rebholz C, Sang Y, Lee A, Coresh J, Selvin E . Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study. Diabetes Care. 2018; 41(8):1646-1653. PMC: 6054502. DOI: 10.2337/dc18-0277. View

Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K . Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021; 17(11):740-750. DOI: 10.1038/s41581-021-00462-y. View

Thomas M, Cooper M, Zimmet P . Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2015; 12(2):73-81. DOI: 10.1038/nrneph.2015.173. View

Gorriz J, Soler M, Navarro-Gonzalez J, Garcia-Carro C, Puchades M, DMarco L . GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med. 2020; 9(4). PMC: 7231090. DOI: 10.3390/jcm9040947. View

Yamamoto Y, Hanai K, Mori T, Yokoyama Y, Yoshida N, Murata H . Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency. Diabetologia. 2021; 65(1):234-245. DOI: 10.1007/s00125-021-05590-5. View

. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S):S1-S115. DOI: 10.1016/j.kint.2020.06.019. View

Kopel J, Pena-Hernandez C, Nugent K . Evolving spectrum of diabetic nephropathy. World J Diabetes. 2019; 10(5):269-279. PMC: 6522757. DOI: 10.4239/wjd.v10.i5.269. View

10.

Bermejo S, Garcia-Carro C, Soler M . Diabetes and renal disease-should we biopsy?. Nephrol Dial Transplant. 2019; 36(8):1384-1386. DOI: 10.1093/ndt/gfz248. View

11.

Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M . Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2008; 24(4):1212-9. DOI: 10.1093/ndt/gfn603. View

12.

Kramer H, Nguyen Q, Curhan G, Hsu C . Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289(24):3273-7. DOI: 10.1001/jama.289.24.3273. View

13.

Shi S, Ni L, Gao L, Wu X . Comparison of Nonalbuminuric and Albuminuric Diabetic Kidney Disease Among Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2022; 13:871272. PMC: 9203723. DOI: 10.3389/fendo.2022.871272. View

14.

Wei T, Zhao L, Jia J, Xia H, Du Y, Lin Q . Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice. Sci Rep. 2015; 5:11998. PMC: 4493693. DOI: 10.1038/srep11998. View

15.

Zurbig P, Jerums G, Hovind P, MacIsaac R, Mischak H, Nielsen S . Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012; 61(12):3304-13. PMC: 3501878. DOI: 10.2337/db12-0348. View

16.

Kume S, Araki S, Ugi S, Morino K, Koya D, Nishio Y . Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2018; 10(4):1032-1040. PMC: 6626952. DOI: 10.1111/jdi.12977. View

17.

Laranjinha I, Matias P, Mateus S, Aguiar F, Pereira P, Perneta Santos M . Diabetic kidney disease: Is there a non-albuminuric phenotype in type 2 diabetic patients?. Nefrologia. 2016; 36(5):503-509. DOI: 10.1016/j.nefro.2016.03.025. View

18.

Tong X, Yu Q, Ankawi G, Pang B, Yang B, Yang H . Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results. Diabetes Ther. 2020; 11(9):1983-1999. PMC: 7434810. DOI: 10.1007/s13300-020-00888-w. View

19.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

20.

Korbut A, Klimontov V, Vinogradov I, Romanov V . Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes. 2019; 10(11):517-533. PMC: 6885724. DOI: 10.4239/wjd.v10.i11.517. View